Agilent Launches Advanced Therapeutics to Unify North American CDMO Services

Agilent Technologies has addressed the growing complexity of drug development by launching Agilent Advanced Therapeutics, a unified Contract Development and Manufacturing Organization (CDMO). This strategic move integrates formerly separate entities — specifically BIOVECTRA in Canada and Nucleic Acid Solutions in Colorado — into a single, streamlined infrastructure. Unlike fragmented service providers, this unified model is designed to provide pharmaceutical and biotech companies with a seamless transition from initial discovery through to commercial-scale production without the need for multiple vendor handoffs.

Unified Infrastructure for End-to-End Development
The primary differentiator of this new entity is its ability to offer an integrated experience across the entire therapeutic lifecycle. By consolidating regional expertise into one platform, the organization removes the logistical and technical silos that often delay the speed-to-market for life-changing therapies. This approach allows partners to access a centralized team that manages everything from process development to large-scale manufacturing under a single partnership agreement, providing a level of continuity that is frequently absent in traditional, multi-vendor outsourcing arrangements.

Specialized Technical Capabilities and Scalability
The portfolio managed by this integrated division covers a broad spectrum of modern medicine requirements. This includes specialized production for oligonucleotides, microbial fermentation, and complex synthetic chemistry. Furthermore, the facility footprint supports the development of highly potent APIs (Active Pharmaceutical Ingredients), bioreagents, and cell line development. By maintaining these diverse capabilities within one ecosystem, the organization ensures that high-purity and high-potency products can be scaled efficiently, meeting the rigorous technical demands of the next generation of therapeutics.

Strategic Market Positioning
This transition reflects an industry-wide shift toward deeper technical partnerships rather than simple transactional manufacturing. By unifying its North American operations, the company provides a more robust and scalable solution for global partners. The integration is intended to simplify the supply chain and enhance technical collaboration, positioning the company as a leading partner for organizations seeking a cohesive and technically advanced manufacturing strategy.

Edited by an industrial journalist, Evgeny Churilov

www.agilent.com